Successful treatment of NDM-1 Klebsiella pneumoniae bacteraemia in a neutropenic patient

Scand J Infect Dis. 2012 Apr;44(4):312-4. doi: 10.3109/00365548.2011.633549. Epub 2011 Nov 29.

Abstract

The rapid emergence of novel multidrug-resistant organisms coupled with the slow development of new antibiotics is of great concern. With the discovery of New Delhi metallo-beta-lactamase 1 (NDM-1)-producing Klebsiella pneumoniae, clinicians are faced with problems in the treatment of infections caused by this multidrug-resistant organism. Therapeutic experiences are limited. We share our experience of the successful treatment of a febrile neutropenic patient with NDM-1-producing K. pneumoniae bacteraemia.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Anti-Bacterial Agents / therapeutic use
  • Bacteremia / drug therapy
  • Bacteremia / microbiology
  • Drug Resistance, Multiple, Bacterial
  • Female
  • Humans
  • Klebsiella Infections / blood
  • Klebsiella Infections / drug therapy*
  • Klebsiella Infections / microbiology
  • Klebsiella pneumoniae / drug effects
  • Klebsiella pneumoniae / enzymology
  • Klebsiella pneumoniae / isolation & purification
  • Neutropenia / microbiology
  • Polymyxin B / therapeutic use
  • beta-Lactamases / biosynthesis*

Substances

  • Anti-Bacterial Agents
  • beta-Lactamases
  • beta-lactamase NDM-1
  • Polymyxin B